4.5 Article

Mechanism and consequence of the autoactivation of p38α mitogen-activated protein kinase promoted by TAB1

期刊

NATURE STRUCTURAL & MOLECULAR BIOLOGY
卷 20, 期 10, 页码 1182-+

出版社

NATURE PUBLISHING GROUP
DOI: 10.1038/nsmb.2668

关键词

-

资金

  1. UK Medical Research Council (MRC) [G0802033, G1001138, J007501]
  2. UK Department of Health through the National Institute for Health Research comprehensive Biomedical Research Centre award
  3. Wellcome Trust [085944/Z/08/Z, 092809/Z/10/Z]
  4. Structural Genomics Consortium [1097737]
  5. AbbVie
  6. Boehringer Ingelheim
  7. Canada Foundation for Innovation
  8. Canadian Institutes for Health Research
  9. Genome Canada
  10. GlaxoSmithKline
  11. Janssen
  12. Lilly Canada
  13. Novartis Research Foundation
  14. Ontario Ministry of Economic Development and Innovation
  15. Pfizer
  16. Takeda
  17. European Union [278568]
  18. MRC [G1001138, MR/J007501/1, G0802033, MC_U117533887] Funding Source: UKRI
  19. Wellcome Trust [085944/Z/08/Z] Funding Source: Wellcome Trust
  20. Medical Research Council [MC_U117533887, G1001138, MR/J007501/1, G0802033] Funding Source: researchfish

向作者/读者索取更多资源

p38 alpha mitogen-activated protein kinase (p38 alpha) is activated by a variety of mechanisms, including autophosphorylation initiated by TGF beta-activated kinase 1 binding protein 1 (TAB1) during myocardial ischemia and other stresses. Chemical-genetic approaches and coexpression in mammalian, bacterial and cell-free systems revealed that mouse p38 alpha autophosphorylation occurs in cis by direct interaction with TAB1(371-416). In isolated rat cardiac myocytes and perfused mouse hearts, TAT-TAB1(371-416) rapidly activates p38 and profoundly perturbs function. Crystal structures and characterization in solution revealed a bipartite docking site for TAB1 in the p38 alpha C-terminal kinase lobe. TAB1 binding stabilizes active p38 alpha and induces rearrangements within the activation segment by helical extension of the Thr-Gly-Tyr motif, allowing autophosphorylation in cis. Interference with p38 alpha recognition by TAB1 abolishes its cardiac toxicity. Such intervention could potentially circumvent the drawbacks of clinical pharmacological inhibitors of p38 catalytic activity.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据